Valuation: Cytogen, Inc.

Market Cap 52.15B 39.06M 35.48M 32.79M 29.61M 55.89M 3.67B 57.85M 394M 156M 1.97B 147M 143M 6.23B P/E 2024
-5.98x
P/E 2025 -16.8x
Enterprise Value 36.92B 27.65M 25.12M 23.21M 20.96M 39.56M 2.6B 40.95M 279M 111M 1.39B 104M 102M 4.41B EV / Sales 2024
7.17x
EV / Sales 2025 7.38x
Free-Float
58.21%
Yield 2024 *
-
Yield 2025 -
1 day-2.80%
1 week+3.20%
Current month-2.59%
1 month-16.33%
3 months-37.19%
6 months-56.88%
Current year-74.92%
1 week 2,220
Extreme 2220.00000000
2,400
1 month 2,100
Extreme 2100
2,850
Current year 2,100
Extreme 2100
11,200
1 year 2,100
Extreme 2100
11,200
3 years 2,100
Extreme 2100
16,640
5 years 2,100
Extreme 2100
23,066.67
10 years 2,100
Extreme 2100
24,166.67
Manager TitleAgeSince
Chief Executive Officer 45 02/01/2025
Chief Executive Officer 67 02/01/2025
Corporate Officer/Principal 52 31/03/2025
Director TitleAgeSince
Director/Board Member 67 02/01/2025
Director/Board Member 45 02/01/2025
Director/Board Member 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
2/1/24 Sell 3,662,748 19.1875%
Change 5-day change 1-year change 3-year change Capi.($)
-2.80%+3.20%-26.90%-85.79% 39.06M
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.48%-0.95%+8.03%+89.25% 60.41B
-0.69%+0.82%+23.54%+87.72% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
-1.46%-2.74%+76.31%+57.10% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -1.16%-1.36%+29.01%+149.83% 41B
Weighted average by Cap. -1.12%-1.58%+34.60%+150.03%

Financials

2024 2025
Net sales 10.91B 8.17M 7.42M 6.86M 6.2M 11.69M 767M 12.1M 82.49M 32.68M 412M 30.66M 30.01M 1.3B 26.05B 19.51M 17.73M 16.38M 14.8M 27.92M 1.83B 28.9M 197M 78.05M 983M 73.22M 71.67M 3.11B
Net income -17.12B -12.82M -11.65M -10.76M -9.72M -18.34M -1.2B -18.99M -129M -51.27M -646M -48.1M -47.09M -2.05B -12.34B -9.24M -8.4M -7.76M -7.01M -13.23M -868M -13.69M -93.31M -36.97M -466M -34.69M -33.95M -1.48B
Net Debt -26.39B -19.77M -17.96M -16.59M -14.99M -28.29M -1.86B -29.28M -200M -79.07M -996M -74.18M -72.61M -3.16B -15.23B -11.41M -10.36M -9.58M -8.65M -16.32M -1.07B -16.9M -115M -45.63M -575M -42.81M -41.9M -1.82B
Projected Income Statement - Annual - Cytogen, Inc.
Logo Cytogen, Inc.
Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.
Employees
42
Date Price Change Volume
16/11/26 KRW 2,255.00 -2.80% 56,227
13/11/26 KRW 2,320.00 0.00% 29,657
12/11/26 KRW 2,320.00 -0.43% 26,670
11/11/26 KRW 2,330.00 +4.48% 42,201
10/11/26 KRW 2,230.00 +2.06% 23,309
  1. Stock Market
  2. Stocks
  3. A217330 Stock